Mikhaeel NG. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. European Journal of Nuclear Medicine and Molecular Imaging 2006 (July); 33, Suppl 13: 22 - 26 Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after 2-3 cycles of chemotherapy predicts progression-free and overall survival in high-grade Non-Hodgkin Lymphoma. Annal Onccol 2005 Sept; 16(9):1514-23 Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of FDG-PET after 2-3 cycles of chemotherapy in Hodgkin Lymphoma. Annal Oncol 2005 Jul; 16(7):1160-8 Mikhaeel NG, Timothy AR, O'Doherty MJ, and Maisey MN. FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT. Leukemia and Lymphoma 2000: 39; 543. Mikhaeel NG, Timothy AR, Hain S, and O'Doherty M. 18-FDG-PET for Assessment of Residual Masses on CT after Treatment of Lymphomas. Annals of Oncology 2000; 11 (1 Suppl): 147-150.